2245966-28-1
2245966-28-1
Chemical Structure
Daxdilimab
Synonym(s): MEDI7734; VIB7734
- CAS No.: 2245966-28-1
- Formula:N/A
- Molecular Weight:(144.38 kDa)
SMILES: [Daxdilimab]
Biological Activity: Daxdilimab (MEDI7734; VIB7734) is a monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7) that depletes plasmacytoid dendritic cells and reduces IFN1 production by binding to the plasmacytoid dendritic cell-specific surface molecule ILT7 and recruiting effector natural killer cells. Daxdilimab (MEDI7734; VIB7734) can be used for research on systemic lupus erythematosus, systemic sclerosis, and polymyositis[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Daxdilimab | 97.82% | Daxdilimab (MEDI7734; VIB7734) is a monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7) that depletes plasmacytoid dendritic cells and reduces IFN1 production by binding to the plasmacytoid dendritic cell-specific surface molecule ILT7 and recruiting effector natural killer cells. Daxdilimab (MEDI7734; VIB7734) can be used for research on systemic lupus erythematosus, systemic sclerosis, and polymyositis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Volkova A, et al. An Integrative Mechanistic Model of Type 1 IFN-Mediated Inflammation in Systemic Lupus Erythematosus. CPT: pharmacometrics & systems pharmacology. 2025 Jul;14(7):1225-1235.
- [2]. Sierra-Sepúlveda A, et al. Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast. BioMed research international. 2019;2019:4569826.
- [3]. Mann H, et al. Clinical Trials in Myositis: Where Do We Stand?. Curr Treat Options in Rheum 7, 222–242 (2021).
- [4]. Werth VP, et al. Plasmacytoid dendritic cells in systemic and cutaneous lupus erythematosus: an evolving understanding. Frontiers in immunology. 2026;17:1807771.
